Vivid Genomics - About the company
Vivid Genomics is a seed company based in San Diego (United States), founded in 2018 by Julie Collens. It operates as a Developer of diagnostic tests for neurodegenerative diseases. Vivid Genomics has raised $20K in funding from Ad Astra Ventures. The company has 400 active competitors, including 135 funded and 89 that have exited. Its top competitors include companies like Human Longevity, Juno Therapeutics and Caris Life Sciences.
Company Details
Vivid Genomics is a developer of diagnostic tests for neurodegenerative diseases. The company is developing blood-based, genetic tests for diagnosing neurodegenerative diseases such as dementia and Alzheimer's disease. The genomic biopsy tests developed are AmyloidGB and ProgressionGB for Alzheimer's disease.
- Website
- vividgenomics.com
- Social
- Email ID
- *****@vividgenomics.com
Key Metrics
Founded Year
2018
Location
San Diego, United States
Stage
Seed
Total Funding
$20K in 2 rounds
Latest Funding Round
Investors
Ranked
178th among 400 active competitors
Employee Count
5 as on Jul 01, 2024
Similar Companies
Sign up to download Vivid Genomics' company profile
Vivid Genomics's funding and investors
Vivid Genomics has raised a total funding of $20K over 2 rounds. Its first funding round was on Oct 25, 2018. Its latest funding round was a Grant (prize money) round on Jun 01, 2022 for $*****. 1 investor participated in its latest round. Vivid Genomics has 4 institutional investors.
Here is the list of recent funding rounds of Vivid Genomics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 01, 2022 | 2317064 | Grant (prize money) | 1603435 | 9587789 | 4661763 | 2088777 |
Oct 25, 2018 | 8486210 | Seed | 4526240 | 6699801 | 1084235 |
Access funding benchmarks and valuations. Sign up today!View details of Vivid Genomics's funding rounds and investors
Vivid Genomics' founders and board of directors
Founder? Claim ProfileThe founders of Vivid Genomics is Julie Collens.
Here are the details of Vivid Genomics' key team members:
- Julie Collens: CEO and Founder of Vivid Genomics.
View details of Vivid Genomics's Founder profiles and Board Members
Vivid Genomics' employee count trend
Vivid Genomics has 5 employees as of Jul 24. Here is Vivid Genomics's employee count trend over the years:
Uncover Vivid Genomics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Vivid Genomics's Competitors and alternates
Top competitors of Vivid Genomics include Human Longevity, Juno Therapeutics and Caris Life Sciences. Here is the list of Top 10 competitors of Vivid Genomics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Human Longevity 2013, San Diego (United States), Series B | Provider of precision medicine, preventative health assessments, and longevity care | $409M | 76/100 | |
2nd | Juno Therapeutics 2013, Seattle (United States), Acquired | Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $317M | 74/100 | |
3rd | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 72/100 | |
4th |  UniQure 1998, Amsterdam (Netherlands), Public | Developer of gene-based therapies for patients with genetic or acquired diseases | $111M | 70/100 | |
5th | Orchard Therapeutics 2015, London (United Kingdom), Acquired | Developer of gene therapies for treating rare diseases | $440M | 70/100 | |
6th | Castle Biosciences 2008, Friendswood (United States), Public | Provider of diagnostic devices for treating cancer | $62M | 70/100 | |
7th | Bluebird Bio 1992, Cambridge (United States), Acquired | Developer of gene therapies for severe genetic and rare diseases | $136M | 70/100 | |
8th | Congenica 2013, Cambridge (United Kingdom), Acquired | Provider of a platform for clinical genome analytics for treating patients with genetic diseases | $81.9M | 69/100 | |
9th | Geneoscopy 2015, St. Louis (United States), Series C | Developer of non-invasive biomarker tests for colorectal cancer | $219M | 68/100 | |
10th | ProQR Therapeutics 2012, Leiden (Netherlands), Public | Developer of RNA-based therapeutics for the treatment of genetic disorders such as inherited retinal disorders | $58M | 65/100 | |
178th | Vivid Genomics 2018, San Diego (United States), Seed | Developer of diagnostic tests for neurodegenerative diseases | $20K | 34/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Vivid Genomics's competitors? Click here to see the top ones
Vivid Genomics's Investments and acquisitions
Vivid Genomics has made no investments or acquisitions yet.
Are you a Founder ?
FAQs about Vivid Genomics
Explore our recently published companies
- Altrisk - 1997 founded, Unfunded company
- Snoozer - Una based, 1995 founded, Public company
- Seatingsymposium - Unfunded company
- FTA HSRP Solutions - Gandhinagar based, 2012 founded, Unfunded company
- Vibrant TMT - Ahmedabad based, 2012 founded, Unfunded company
- Primetoolings.com - 2025 founded, Unfunded company
